Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2014
Price :
$35
*
At a glance
- Drugs Palifermin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2009 New trial record.